Reneo Pharmaceuticals

Aug 11, 2021

•

Jun 30, 2021

Reneo Pharmaceuticals Q2 2021 Earnings Report

Reneo Pharmaceuticals reported a net loss for Q2 2021 and provided an update on its clinical programs.

Key Takeaways

Reneo Pharmaceuticals reported a net loss of $9.2 million, or $0.43 per share, for the three months ended June 30, 2021. The company had $167.3 million in cash, cash equivalents and short-term investments as of June 30, 2021.

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies.

Completed enrollment of study REN001-103 in patients with glycogen storage disease type V (McArdle disease).

Dosed 20 patients to date in study REN001-102 in patients with long-chain fatty acid oxidation disorder (LC-FAOD).

Enrolled 18 patients to date in the FORWARD study in patients with LC-FAOD.